Meds & supplements › Dacomitinib
Medicine
Dacomitinib
VIZIMPRO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an…
Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗
Drug facts
- Used for
- VIZIMPRO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an…
What it is used for
VIZIMPRO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.
Side effects, and when to stop
The following adverse drug reactions are described elsewhere in the labeling:
- Interstitial Lung Disease
- Diarrhea
- Dermatologic Adverse Reactions
Who should not take it
None.
Storing it
Store at 20 °C to 25 °C (68 °F to 77 °F); excursions permitted between 15 °C to 30 °C (59 °F to 86 °F)..
Cite this page
- NLM
sofidex [Internet]. Daloreum; c2026. Dacomitinib; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/dacomitinib
- APA 7th
sofidex. (2026, August 2). Dacomitinib. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/dacomitinib
- AMA 11th
Dacomitinib. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/dacomitinib
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.